Beyond NSCLC, IL-1β has been implicated in breast, gastric, and colorectal cancers, where it contributes to tumor growth, metastasis, and therapy resistance [6,12,18,19]. This evidence concerns the gene IL1B and non-small cell lung carcinoma.